Abstract
The design and synthesis of substituted 1-(1-ethy-1H-benzimidazol-2-yl) ethanone (3a-f) and substituted 1-(2-bromoethyl)-2- (1-hydrazinylidene or ethylidene)-1H-benzimidazole (3g-j) have been successfully achieved under microwave irradiation with an aim for finding promising anticancer agents. Among the synthetic compounds, those with potential activity were selected and evaluated in-vitro for anticancer activity at the National Cancer Institute (NCI), USA, against 60 cancer cell lines from nine types of human cancer. The title compound 3e (NSC: 765733/1) exhibited notable growth inhibition that satisfies threshold criteria at single dose (10 µM) on all human cell lines of NCI. This compound was considered for further study at five dose levels (0.01, 0.1, 1, 10 and 100 µM) with GI50 values ranging from 0.19 to 92.7 µM. Compound 3e was found superior for Non-small cell lung cancer cell lines (HOP-92) and calculated end points (GI50 0.19, TGI 1.45, LC50 >100 and Log10GI50 -6.70, Log10TGI -5.84, Log10LC50 >-4.00). Docking study was performed using Maestro 9.0 to provide binding mode into binding sites of topoisomerase enzyme (PDB ID: 1SC7). Hopefully in the future, compound 3e could be used as novel template for the development of potential anticancer agents.
Keywords: Anticancer compounds, bendamustine, benzimidazole, chlorambucil, NCI-60 human cell lines, sulforhodamine B.
Anti-Cancer Agents in Medicinal Chemistry
Title:Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Volume: 14 Issue: 7
Author(s): Mohd Rashid, Asif Husain, Mohammad Shaharyar and Mohd Sarafroz
Affiliation:
Keywords: Anticancer compounds, bendamustine, benzimidazole, chlorambucil, NCI-60 human cell lines, sulforhodamine B.
Abstract: The design and synthesis of substituted 1-(1-ethy-1H-benzimidazol-2-yl) ethanone (3a-f) and substituted 1-(2-bromoethyl)-2- (1-hydrazinylidene or ethylidene)-1H-benzimidazole (3g-j) have been successfully achieved under microwave irradiation with an aim for finding promising anticancer agents. Among the synthetic compounds, those with potential activity were selected and evaluated in-vitro for anticancer activity at the National Cancer Institute (NCI), USA, against 60 cancer cell lines from nine types of human cancer. The title compound 3e (NSC: 765733/1) exhibited notable growth inhibition that satisfies threshold criteria at single dose (10 µM) on all human cell lines of NCI. This compound was considered for further study at five dose levels (0.01, 0.1, 1, 10 and 100 µM) with GI50 values ranging from 0.19 to 92.7 µM. Compound 3e was found superior for Non-small cell lung cancer cell lines (HOP-92) and calculated end points (GI50 0.19, TGI 1.45, LC50 >100 and Log10GI50 -6.70, Log10TGI -5.84, Log10LC50 >-4.00). Docking study was performed using Maestro 9.0 to provide binding mode into binding sites of topoisomerase enzyme (PDB ID: 1SC7). Hopefully in the future, compound 3e could be used as novel template for the development of potential anticancer agents.
Export Options
About this article
Cite this article as:
Rashid Mohd, Husain Asif, Shaharyar Mohammad and Sarafroz Mohd, Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1871520614666140509153021
DOI https://dx.doi.org/10.2174/1871520614666140509153021 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX-Tumor-Associated (Hypoxia)
Letters in Drug Design & Discovery Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Cancer-Homing Toxins
Current Pharmaceutical Design Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Current Topics in Medicinal Chemistry Constructing a Risk Prediction Model for Lung Cancer Recurrence by Using Gene Function Clustering and Machine Learning
Combinatorial Chemistry & High Throughput Screening A QSAR Study on a Series of Pyrrole Derivatives Acting as Lymphocyte- Specific Kinase (Lck) Inhibitors
Medicinal Chemistry Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Plasma Metabolome Signature in Patients with Early-stage Parkinson Disease
Current Metabolomics Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth
Anti-Cancer Agents in Medicinal Chemistry NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Berberine: A Fluorescent Alkaloid with a Variety of Applications from Medicine to Chemistry
Mini-Reviews in Organic Chemistry HUHS1015 Induces Necroptosis and Caspase-Independent Apoptosis of MKN28 Human Gastric Cancer Cells in Association with AMID Accumulation in the Nucleus
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy